38 research outputs found
Π€ΠΈΠ±ΡΠΎΠ·ΠΈΡΡΡΡΠ°Ρ Π°ΡΡΡΠΎΠΏΠ°ΡΠΈΡ ΠΏΡΠΈ ΡΠ²Π΅Π½ΠΈΠ»ΡΠ½ΠΎΠΉ ΡΠΊΠ»Π΅ΡΠΎΠ΄Π΅ΡΠΌΠΈΠΈ
The group of scleroderma diseases includes a number of clinical entities, the main symptom of which is skin tightening. Scleroderma is a prominent example of these diseases, characterized by excessive synthesis and deposition of collagen in organs and tissues. A patient with juvenile systemic scleroderma with induration of the skin and underlying tissues, and persistent contractures of large joints since childhood, is described. This clinical example illustrates disease course peculiarities and differential diagnosis of systemic and limited (focal) scleroderma and scleroderma-like conditions in pediatric patients. The feasibility of pathogenetic therapy aimed at improving patient's the quality of life with formed disease phenotype is shown.Π Π³ΡΡΠΏΠΏΠ΅ ΡΠΊΠ»Π΅ΡΠΎΠ΄Π΅ΡΠΌΠΈΡΠ΅ΡΠΊΠΈΡ
Π±ΠΎΠ»Π΅Π·Π½Π΅ΠΉ ΠΎΡΠ½ΠΎΡΠΈΡΡΡ ΡΡΠ΄ Π½ΠΎΠ·ΠΎΠ»ΠΎΠ³ΠΈΠΉ, ΠΎΡΠ½ΠΎΠ²Π½ΡΠΌ ΠΏΡΠΈΠ·Π½Π°ΠΊΠΎΠΌ ΠΊΠΎΡΠΎΡΡΡ
ΡΠ²Π»ΡΠ΅ΡΡΡ ΡΠΏΠ»ΠΎΡΠ½Π΅Π½ΠΈΠ΅ ΠΊΠΎΠΆΠΈ. Π‘ΠΊΠ»Π΅ΡΠΎΠ΄Π΅ΡΠΌΠΈΡ β ΡΡΠΊΠΈΠΉ ΠΏΡΠ΅Π΄ΡΡΠ°Π²ΠΈΡΠ΅Π»Ρ ΡΡΠΈΡ
Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΠΉ, Ρ
Π°ΡΠ°ΠΊΡΠ΅ΡΠΈΠ·ΡΡΡΠΈΡ
ΡΡ ΠΈΠ·Π±ΡΡΠΎΡΠ½ΡΠΌ ΡΠΈΠ½ΡΠ΅Π·ΠΎΠΌ ΠΈ ΠΎΡΠ»ΠΎΠΆΠ΅Π½ΠΈΠ΅ΠΌ ΠΊΠΎΠ»Π»Π°Π³Π΅Π½Π° Π² ΠΎΡΠ³Π°Π½Π°Ρ
ΠΈ ΡΠΊΠ°Π½ΡΡ
. ΠΠΏΠΈΡΠ°Π½Π° Π±ΠΎΠ»ΡΠ½Π°Ρ ΡΠ²Π΅Π½ΠΈΠ»ΡΠ½ΠΎΠΉ ΡΠΈΡΡΠ΅ΠΌΠ½ΠΎΠΉ ΡΠΊΠ»Π΅ΡΠΎΠ΄Π΅ΡΠΌΠΈΠ΅ΠΉ Ρ ΠΈΠ½Π΄ΡΡΠ°ΡΠΈΠ΅ΠΉ ΠΊΠΎΠΆΠΈ ΠΈ ΠΏΠΎΠ΄Π»Π΅ΠΆΠ°ΡΠΈΡ
ΡΠΊΠ°Π½Π΅ΠΉ, Π° ΡΠ°ΠΊΠΆΠ΅ ΡΡΠΎΠΉΠΊΠΈΠΌΠΈ ΠΊΠΎΠ½ΡΡΠ°ΠΊΡΡΡΠ°ΠΌΠΈ ΠΊΡΡΠΏΠ½ΡΡ
ΡΡΡΡΠ°Π²ΠΎΠ² Ρ Π΄Π΅ΡΡΠΊΠΎΠ³ΠΎ Π²ΠΎΠ·ΡΠ°ΡΡΠ°. ΠΠ° ΡΡΠΎΠΌ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΎΠΌ ΠΏΡΠΈΠΌΠ΅ΡΠ΅ ΡΠ°ΡΡΠΌΠ°ΡΡΠΈΠ²Π°ΡΡΡΡ ΠΎΡΠΎΠ±Π΅Π½Π½ΠΎΡΡΠΈ ΡΠ΅ΡΠ΅Π½ΠΈΡ ΠΈ Π΄ΠΈΡΡΠ΅ΡΠ΅Π½ΡΠΈΠ°Π»ΡΠ½Π°Ρ Π΄ΠΈΠ°Π³Π½ΠΎΡΡΠΈΠΊΠ° ΡΠΈΡΡΠ΅ΠΌΠ½ΠΎΠΉ ΠΈ ΠΎΠ³ΡΠ°Π½ΠΈΡΠ΅Π½Π½ΠΎΠΉ (ΠΎΡΠ°Π³ΠΎΠ²ΠΎΠΉ) ΡΠΊΠ»Π΅ΡΠΎΠ΄Π΅ΡΠΌΠΈΠΈ ΠΈ ΡΠΊΠ»Π΅ΡΠΎΠ΄Π΅ΡΠΌΠΎΠΏΠΎΠ΄ΠΎΠ±Π½ΡΡ
ΡΠΎΡΡΠΎΡΠ½ΠΈΠΉ Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Π΄Π΅ΡΡΠΊΠΎΠ³ΠΎ Π²ΠΎΠ·ΡΠ°ΡΡΠ°. ΠΠΎΠΊΠ°Π·Π°Π½Ρ Π²ΠΎΠ·ΠΌΠΎΠΆΠ½ΠΎΡΡΠΈ ΠΏΠΎΠ΄Π±ΠΎΡΠ° ΠΏΠ°ΡΠΎΠ³Π΅Π½Π΅ΡΠΈΡΠ΅ΡΠΊΠΎΠΉ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ, Π½Π°ΠΏΡΠ°Π²Π»Π΅Π½Π½ΠΎΠΉ Π½Π° ΡΠ»ΡΡΡΠ΅Π½ΠΈΠ΅ ΠΊΠ°ΡΠ΅ΡΡΠ²Π° ΠΆΠΈΠ·Π½ΠΈ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ ΡΠΆΠ΅ ΡΡΠΎΡΠΌΠΈΡΠΎΠ²Π°Π½Π½ΡΠΌ ΡΠ΅Π½ΠΎΡΠΈΠΏΠΎΠΌ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡ
ΠΠΎΠΌΠΏΠ»Π΅ΠΊΡΠ½Π°Ρ ΡΠ΅ΡΠ°ΠΏΠΈΡ ΡΠΎΡΡΠ΄ΠΈΡΡΡΡ Π½Π°ΡΡΡΠ΅Π½ΠΈΠΉ Ρ Π±ΠΎΠ»ΡΠ½ΡΡ ΡΠΈΡΡΠ΅ΠΌΠ½ΠΎΠΉ ΡΠΊΠ»Π΅ΡΠΎΠ΄Π΅ΡΠΌΠΈΠ΅ΠΉ
Scleroderma systematica (SDS) is a disease in which vascular diseases underlie the pathogenesis and presented by diverse clinical manifestations. Raynaud's syndrome and digital ulceration are the most common symptom of the diseases, which influences the quality of life in patients and requires continuous drug therapy. The paper discusses the recent European guidelines for the management of this manifestation of SDS. The proposed recommendations cannot unfortunately be realized in full measure now due to the unavailability of some drugs. The authors give their clinical experience with therapy for the vascular manifestations of SDS.Π‘ΠΈΡΡΠ΅ΠΌΠ½Π°Ρ ΡΠΊΠ»Π΅ΡΠΎΠ΄Π΅ΡΠΌΠΈΡ (Π‘Π‘Π) - Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΠ΅, ΠΏΡΠΈ ΠΊΠΎΡΠΎΡΠΎΠΌ ΡΠΎΡΡΠ΄ΠΈΡΡΡΠ΅ Π½Π°ΡΡΡΠ΅Π½ΠΈΡ Π»Π΅ΠΆΠ°Ρ Π² ΠΎΡΠ½ΠΎΠ²Π΅ ΠΏΠ°ΡΠΎΠ³Π΅Π½Π΅Π·Π° ΠΈ ΠΏΡΠ΅Π΄ΡΡΠ°Π²Π»Π΅Π½Ρ ΡΠ°Π·Π½ΠΎΠΎΠ±ΡΠ°Π·Π½ΡΠΌΠΈ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΈΠΌΠΈ ΠΏΡΠΎΡΠ²Π»Π΅Π½ΠΈΡΠΌΠΈ. Π‘ΠΈΠ½Π΄ΡΠΎΠΌ Π Π΅ΠΉΠ½ΠΎ ΠΈ ΠΎΠ±ΡΠ°Π·ΠΎΠ²Π°Π½ΠΈΠ΅ Π΄ΠΈΠ³ΠΈΡΠ°Π»ΡΠ½ΡΡ
ΡΠ·Π² - Π½Π°ΠΈΠ±ΠΎΠ»Π΅Π΅ ΡΠ°ΡΡΡΠΉ ΡΠΈΠΌΠΏΡΠΎΠΌ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡ, Π²Π»ΠΈΡΡΡΠΈΠΉ Π½Π° ΠΊΠ°ΡΠ΅ΡΡΠ²ΠΎ ΠΆΠΈΠ·Π½ΠΈ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² ΠΈ ΡΡΠ΅Π±ΡΡΡΠΈΠΉ ΠΏΠΎΡΡΠΎΡΠ½Π½ΠΎΠΉ Π»Π΅ΠΊΠ°ΡΡΡΠ²Π΅Π½Π½ΠΎΠΉ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ. Π ΡΡΠ°ΡΡΠ΅ ΠΎΠ±ΡΡΠΆΠ΄Π°ΡΡΡΡ Π½Π΅Π΄Π°Π²Π½ΠΎ ΠΎΠΏΡΠ±Π»ΠΈΠΊΠΎΠ²Π°Π½Π½ΡΠ΅ Π΅Π²ΡΠΎΠΏΠ΅ΠΉΡΠΊΠΈΠ΅ ΡΠ΅ΠΊΠΎΠΌΠ΅Π½Π΄Π°ΡΠΈΠΈ ΠΏΠΎ Π»Π΅ΡΠ΅Π½ΠΈΡ ΡΡΠΎΠ³ΠΎ ΠΏΡΠΎΡΠ²Π»Π΅Π½ΠΈΡ Π‘Π‘Π. ΠΡΠΏΠΎΠ»Π½Π΅Π½ΠΈΠ΅ ΠΏΡΠ΅Π΄Π»ΠΎΠΆΠ΅Π½Π½ΡΡ
ΡΠ΅ΠΊΠΎΠΌΠ΅Π½Π΄Π°ΡΠΈΠΉ Π² ΠΏΠΎΠ»Π½ΠΎΠΌ ΠΎΠ±ΡΠ΅ΠΌΠ΅, ΠΊ ΡΠΎΠΆΠ°Π»Π΅Π½ΠΈΡ, Π² Π½Π°ΡΡΠΎΡΡΠ΅Π΅ Π²ΡΠ΅ΠΌΡ Π½Π΅Π²ΠΎΠ·ΠΌΠΎΠΆΠ½ΠΎ ΠΈΠ·-Π·Π° Π½Π΅Π΄ΠΎΡΡΡΠΏΠ½ΠΎΡΡΠΈ Π½Π΅ΠΊΠΎΡΠΎΡΡΡ
ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠΎΠ². ΠΠ²ΡΠΎΡΠ°ΠΌΠΈ ΠΏΡΠΈΠ²ΠΎΠ΄ΠΈΡΡΡ ΡΠΎΠ±ΡΡΠ²Π΅Π½Π½ΡΠΉ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΈΠΉ ΠΎΠΏΡΡ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ ΡΠΎΡΡΠ΄ΠΈΡΡΡΡ
ΠΏΡΠΎΡΠ²Π»Π΅Π½ΠΈΠΉ Π‘Π‘Π
SCLERODERMA SYSTEMATICA WITH INTERSTITIAL LUNG LESION: COMPARATIVE CLINICAL CHARACTERISTICSWITH PATIENTS WITHOUT LUNG LESION
Objective. To compare disease history data and clinical and laboratory parameters in patients with scleroderma systematica (SDS) with high-resolution computed tomography (HRCT)-verified interstitial lung lesion (ILL) versus those without lung involvement. Subjects and methods. An examination was made in 138 patients with SDS who had been consecutively admitted in 2006-2008, female/male ratio, 124 : 14; limited : diffuse : mixed forms, 78 : 40 : 20; mean age, 47Β±13 years; median disease duration, 6 (2.5 11) years. The history data (occupational hazards, smoking, respiratory diseases) and clinical manifestations of SDS and laboratory data were studied. The diagnosis of ILL was established on the basis of chest HRCT. Results. According to HRCT data, the signs of varying ILL were found in 82% of the patients with SDS. The duration of SDS was similar in the patients with and without lung involvement; but the latter were younger at the time of disease onset. There were no significant differences between the groups compared in history data, clinical forms of SDS, the frequency of involvement of visceral organs and systems. Crepitation was heard only in the patients with ILL. The frequency of respiratory manifestations increased with a larger number of the involved lung segments. The prevalence of ILL was found to be positively correlated with age at the onset of SDS (r=0.29;
STUDY OF THE EFFICIENCY AND SAFETY OF MYCOPHENOLATE MOFETIL THERAPY IN PATIENTSWITH SYSTEMIC SCLERODERMA
Interstitial lung disease (ILD) is one of the major causes of death in systemic scleroderma (SSD). Treatment of these patients remains difficult and controversial. Mycophenolate mofetil (MPM) has been in vitro shown to inhibit overproduction of type I collagen and hence may be effective against SSD. Objective: to study the efficiency and safety of MPM therapy in patients with SSD and clinically relevant ILD in an open-label prospective study. Subjects and methods. Ten patients with SSD (7 and 3 with its diffuse and limited forms, respectively) and ILD were given MPM in combination with glucocorticoids (mean daily dose was 10+4 mg). The mean MPM therapy duration was 11.4+1.3 months. The Rodnan total skin thickness score, flexion index, forced vital capacity (FVC), diffusing capacity of the lung for carbon monoxide (DLCO), and European Scleroderma Study Group (EScSG) activity index were estimated and a 6-minute walk test (6MWT) was carried out before and after MPM therapy. Results. After therapy, the whole group showed a significant reduction in skin scores from 12.9+9.8 to 5.6+3.2 (p=0.036) and EScSG from 3.9+1.4 to 2.25+1.03 (p=0.015) and an increase in exercise tolerance from 446+155 to 535+78 m (p=0.03) as evidenced by 6MWT. The degree of flexion contractures decreased from 15+21 to 3.7+11.3 mm (p>0.05). FVC (77.8+18.7% versus 73.8+11.3%) and DLCO (45+14.4% versus 42+16.4%) were significantly unchanged. A 10% or more clinically significant fall was noted in FVC and DLCO in 3 and 1 patients, respectively. In the remaining patients, the lung functional test results remained stable. MPM tolerability was satisfactory. All the patients completed their course of treatment. Conclusion. Stabilization of lung function with higher exercise tolerance and significantly reduced skin density allow therapy with MPM in combination with low-dose glucocorticoids to be regarded as an effective and well-tolerated treatment in patients with ILD in the presence of SS
ΠΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½ΠΈΠ΅ ΠΌΠ΅ΠΆΠ΄ΡΠ½Π°ΡΠΎΠ΄Π½ΠΎΠ³ΠΎ ΠΈΠ½Π΄Π΅ΠΊΡΠ° Π΄Π»Ρ ΠΎΡΠ΅Π½ΠΊΠΈ Π°ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈ ΡΠΈΡΡΠ΅ΠΌΠ½ΠΎΠΉ ΡΠΊΠ»Π΅ΡΠΎΠ΄Π΅ΡΠΌΠΈΠΈ
Up to now, it is difficult to determine systemic scleroderma (SSD) activity because of the lack of validated tools to estimate changes in the pathological process. Attempts have been made to develop unified activity assessing methods for many years. The indices proposed by the European SSD Group are most popular today. This paper gives the results of using this index in a cohort of Russian patients.ΠΠΏΡΠ΅Π΄Π΅Π»Π΅Π½ΠΈΠ΅ Π°ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈ ΡΠΈΡΡΠ΅ΠΌΠ½ΠΎΠΉ ΡΠΊΠ»Π΅ΡΠΎΠ΄Π΅ΡΠΌΠΈΠΈ (Π‘Π‘Π) Π΄ΠΎ Π½Π°ΡΡΠΎΡΡΠ΅Π³ΠΎ Π²ΡΠ΅ΠΌΠ΅Π½ΠΈ Π·Π°ΡΡΡΠ΄Π½Π΅Π½ΠΎ ΠΈΠ·-Π·Π° ΠΎΡΡΡΡΡΡΠ²ΠΈΡ Π²Π°Π»ΠΈΠ΄ΠΈΡΠΎΠ²Π°Π½Π½ΡΡ
ΠΈΠ½ΡΡΡΡΠΌΠ΅Π½ΡΠΎΠ² Π΄Π»Ρ ΠΎΡΠ΅Π½ΠΊΠΈ ΠΈΠ·ΠΌΠ΅Π½Π΅Π½ΠΈΠΉ ΠΏΠ°ΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΠΏΡΠΎΡΠ΅ΡΡΠ°. Π ΡΠ΅ΡΠ΅Π½ΠΈΠ΅ ΠΌΠ½ΠΎΠ³ΠΈΡ
Π»Π΅Ρ ΠΏΡΠ΅Π΄ΠΏΡΠΈΠ½ΠΈΠΌΠ°ΡΡΡΡ ΠΏΠΎΠΏΡΡΠΊΠΈ ΡΠΎΠ·Π΄Π°Π½ΠΈΡ ΡΠ½ΠΈΡΠΈΡΠΈΡΠΎΠ²Π°Π½Π½ΡΡ
ΠΌΠ΅ΡΠΎΠ΄ΠΎΠ² ΠΎΡΠ΅Π½ΠΊΠΈ Π°ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡ. ΠΠ°ΠΈΠ±ΠΎΠ»Π΅Π΅ ΠΏΠΎΠΏΡΠ»ΡΡΠ½ΡΠΌΠΈ Π½Π° ΡΠ΅Π³ΠΎΠ΄Π½ΡΡΠ½ΠΈΠΉ Π΄Π΅Π½Ρ ΡΠ²Π»ΡΡΡΡΡ ΠΈΠ½Π΄Π΅ΠΊΡΡ, ΠΏΡΠ΅Π΄Π»ΠΎΠΆΠ΅Π½Π½ΡΠ΅ Π΅Π²ΡΠΎΠΏΠ΅ΠΉΡΠΊΠΎΠΉ Π³ΡΡΠΏΠΏΠΎΠΉ ΠΏΠΎ ΠΈΠ·ΡΡΠ΅Π½ΠΈΡ Π‘Π‘Π. Π ΡΡΠ°ΡΡΠ΅ ΠΏΡΠ΅Π΄ΡΡΠ°Π²Π»Π΅Π½Ρ ΡΠ΅Π·ΡΠ»ΡΡΠ°ΡΡ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½ΠΈΡ ΡΡΠΎΠ³ΠΎ ΠΈΠ½Π΄Π΅ΠΊΡΠ° Ρ ΠΊΠΎΠ³ΠΎΡΡΡ ΡΠΎΡΡΠΈΠΉΡΠΊΠΈΡ
ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ²
Comparative analysis of anxiety-depressive spectrum disorders in patients with rheumatic diseases
Research objective - comparative analysis of incidence and structure of anxiety-depressive spectrum disorders (ADD) in patients with various rheumatic diseases (RD). Materials and methods. 613 patients with RD were enrolled in the study: 180 with a reliable diagnosis of systemic lupus erythematosus (SLE), 128 with rheumatoid arthritis (RA), 110 with systemic sclerosis (SSc), 115 with Behcet's disease (BD), 80 with primary SjΓΆgren's syndrome (pSS). Female prevailed in all groups (95% of patients with pSS, 88,2% - SSc, 87,2% - RA, 85,5% of SLE) except BD patients (70% male). The mean age was 42.3Β±1.54 years and was lower in patients with BD (33.3Β±0.98 years) and SLE (34.6Β±0.93 years) compared to patients with SSc (49.9Β±2.47 years), RA (47.4Β±0.99 years) and pSS (46.2Β±2.3 years). The mean RD duration was 130,0Β±8,65 months and was more at BD - 148,5Β±10,4 months, pSS - 141,6Β±8,92 months, RA - 138,4Β±10,1months, and less at SLE - 134,9Β±8,8 months and SSc - 87,0Β±5,04 months. The mean SLE activity index SLEDAI was 9,13Β±0,63 points (high), RA (DAS28) - 5,26Β±0,17 points (high), BD (BDCAF) - 3,79Β±0,2 points (moderate) and SSc by G. Valentini - 1,1Β±0,20 points (moderate). Glucocorticoids took 100% of patients with pSS, 91,1% - SLE, 90% - SSc, 87% - BD and 67,2% - RA patients; conventional disease modifying anti-rheumatic drugs (cDMARDs) took 90% of patients with SSc, 84% - BD, 79,6% - RA, 68% - pSS, 40,6% - SLE. Biologic DMARDs took 32% of patients with RA, 17,4% - BD, 7,3% - SSc and 7,2% - SLE. Mental disorders were diagnosed by psychiatrist as a result of screening by the hospital anxiety and depression scale (HADS) and in semi-structured interview in accordance with the ICD-10/ DSM-IV. The severity of depression was evaluated by Montgomery-Asberg Depression Rating Scale (MADRS) and anxiety - by Hamilton Anxiety Rating Scale (HAM-A). Projective psychological methods were used for cognitive impairment detection. Results. Screening of depressive disorders (HADS-Dβ₯8) was positive in 180 (29,4%) patients with RD, including 74 (41%) patients with SLE, 38 (35%) - SSc, 29 (23%) - RA, 23 (20%) - BD and 16 (20%) - pSS; anxiety disorders (HADS-Aβ₯8) - in 272 (44,4%) patients, including 66 (52%) patients with RA, 40 (50%) - pSS, 77 (43%) - SLE, 45 (41%) - SSc and 44 (38%) - BD. In accordance with the ICD-10/ DSM-IV depressive disorders have been identified in 389 (63%) patients, including 94 (73%) patients with RA, 71 (64,5%) - SSc, 69 (60%) - BD, 90 (50%) - SLE and 39 (49%) - pSS; anxiety disorders - in 377 (61,5%) patients, including 20 (25%) patients with pSS, 44 (24,5%) - SLE, 29 (23%) - RA, 20 (17%) - BD and 7 (6,4%) - SSc. Conclusion. Anxiety-depressive spectrum disorders are typical for most patients with RA, SLE, SSc, pSS and BD. ADDs diagnosis in RD patients with the use of the HADS did not reveal a significant proportion. To obtain objective data on the frequency and structure of ADDs, psychopathological and clinical psychological diagnosis is necessary
Π€ΡΠ½ΠΊΡΠΈΡ ΠΏΠΎΡΠ΅ΠΊ Π½Π° ΡΠΎΠ½Π΅ Π΄Π»ΠΈΡΠ΅Π»ΡΠ½ΠΎΠΉ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ ΡΠΈΡΡΠΊΡΠΈΠΌΠ°Π±ΠΎΠΌ Ρ Π±ΠΎΠ»ΡΠ½ΡΡ ΡΠΈΡΡΠ΅ΠΌΠ½ΠΎΠΉ ΡΠΊΠ»Π΅ΡΠΎΠ΄Π΅ΡΠΌΠΈΠ΅ΠΉ
Β Β In systemic sclersis (SSc), different types of renal involvement occur. Their severity can range from asymptomatic deterioration of renal function to life-threatening damage, which is a complex therapeutic problem. Rituximab (RTM) has been used in the treatment of SSc and other autoimmune diseases with promising results, but its effect on renal function has not been adequately studied.Β Β Objective:Β to evaluate the renal function during complex therapy, including RTM, in patients with SSc over a long-term follow-up (at least 1 year).Β Β Material and methods.Β The study included 90 patients with SSc who were examined at least twice β before and 1β3.5 years after initiation of RTM treatment. Renal function was assessed by glomerular filtration rate (GFR) calculated according to the CKD-EPI formula. The stages of chronic kidney disease (CKD), blood pressure, daily proteinuria, skin score, activity, and indicators of lung function β forced vital capacity and diffusing capacity of the lungs β were also determined.Β Β Results and discussion.Β Against the background of complex therapy with RTM, there was a statistically significant decrease in GFR in the entire group of patients at the end of observation. On the other hand, renal function remained stable in the majority of patients with initially preserved GFR and there was a 25 % decrease β from 20 to 15 patients β in the number of patients with CKD. In more than half of the patients who initially had CKD, GFR increased (n = 11) or stabilized (n = 2) after therapy, and it decreased in a statistically insignificant manner in only 7 patients, whereas the development of a more advanced stage of CKD was observed in only 2 cases. The results of the treatment of 2 patients who had previously experienced scleroderma renal crisis (SRC) are reviewed in detail.Β Β Conclusion.Β In this study, there was no significant effect of RTM treatment on GFR and grade of CKD. Most patients had stable renal function; patients with an initial low grade of CKD showed a tendency toward stabilization of renal function. A significant decrease in GFR during long-term therapy noted in the entire patient group appears to be explained by an increase in renal insufficiency in patients with initially severe scleroderma renal damage, particularly due to SRC. Further studies on the effects of RTM therapy on renal function in patients with SSc are needed.Β Β ΠΡΠΈ ΡΠΈΡΡΠ΅ΠΌΠ½ΠΎΠΉ ΡΠΊΠ»Π΅ΡΠΎΠ΄Π΅ΡΠΌΠΈΠΈ (Π‘Π‘Π) Π²ΡΡΡΠ΅ΡΠ°ΡΡΡΡ ΡΠ°Π·Π»ΠΈΡΠ½ΡΠ΅ ΡΠΈΠΏΡ ΠΏΠΎΡΠ°ΠΆΠ΅Π½ΠΈΡ ΠΏΠΎΡΠ΅ΠΊ. Π‘ΡΠ΅ΠΏΠ΅Π½Ρ ΠΈΡ
Π²ΡΡΠ°ΠΆΠ΅Π½Π½ΠΎΡΡΠΈ ΠΌΠΎΠΆΠ΅Ρ Π²Π°ΡΡΠΈΡΠΎΠ²Π°ΡΡΡΡ ΠΎΡ Π±Π΅ΡΡΠΈΠΌΠΏΡΠΎΠΌΠ½ΠΎΠ³ΠΎ ΡΠ½ΠΈΠΆΠ΅Π½ΠΈΡ ΠΏΠΎΡΠ΅ΡΠ½ΠΎΠΉ ΡΡΠ½ΠΊΡΠΈΠΈ Π΄ΠΎ ΠΆΠΈΠ·Π½Π΅ΡΠ³ΡΠΎΠΆΠ°ΡΡΠΈΡ
ΠΏΠΎΠ²ΡΠ΅ΠΆΠ΄Π΅Π½ΠΈΠΉ, ΠΊΠΎΡΠΎΡΡΠ΅ ΠΏΡΠ΅Π΄ΡΡΠ°Π²Π»ΡΡΡ ΡΠΎΠ±ΠΎΠΉ ΡΠ»ΠΎΠΆΠ½ΡΡ ΡΠ΅ΡΠ°ΠΏΠ΅Π²ΡΠΈΡΠ΅ΡΠΊΡΡ ΠΏΡΠΎΠ±Π»Π΅ΠΌΡ. Π ΠΈΡΡΠΊΡΠΈΠΌΠ°Π± (Π Π’Π) ΠΏΡΠΈΠΌΠ΅Π½ΡΠ΅ΡΡΡ Π² Π»Π΅ΡΠ΅Π½ΠΈΠΈ Π‘Π‘Π ΠΈ Π΄ΡΡΠ³ΠΈΡ
Π°ΡΡΠΎΠΈΠΌΠΌΡΠ½Π½ΡΡ
Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΠΉ Ρ ΠΌΠ½ΠΎΠ³ΠΎΠΎΠ±Π΅ΡΠ°ΡΡΠΈΠΌΠΈ ΡΠ΅Π·ΡΠ»ΡΡΠ°ΡΠ°ΠΌΠΈ, ΠΎΠ΄Π½Π°ΠΊΠΎ Π΅Π³ΠΎ Π²Π»ΠΈΡΠ½ΠΈΠ΅ Π½Π° ΡΡΠ½ΠΊΡΠΈΡ ΠΏΠΎΡΠ΅ΠΊ ΠΈΠ·ΡΡΠ΅Π½ΠΎ Π½Π΅Π΄ΠΎΡΡΠ°ΡΠΎΡΠ½ΠΎ.Β Β Π¦Π΅Π»Ρ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ β ΠΎΡΠ΅Π½ΠΈΡΡ ΡΠΎΡΡΠΎΡΠ½ΠΈΠ΅ ΡΡΠ½ΠΊΡΠΈΠΈ ΠΏΠΎΡΠ΅ΠΊ Π½Π° ΡΠΎΠ½Π΅ ΠΊΠΎΠΌΠΏΠ»Π΅ΠΊΡΠ½ΠΎΠΉ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ, Π²ΠΊΠ»ΡΡΠ°ΡΡΠ΅ΠΉ Π Π’Π, Ρ Π±ΠΎΠ»ΡΠ½ΡΡ
Π‘Π‘Π Π² ΡΠ΅ΡΠ΅Π½ΠΈΠ΅ Π΄Π»ΠΈΡΠ΅Π»ΡΠ½ΠΎΠ³ΠΎ (Π½Π΅ ΠΌΠ΅Π½Π΅Π΅ 1 Π³ΠΎΠ΄Π°) Π½Π°Π±Π»ΡΠ΄Π΅Π½ΠΈΡ.Β Β ΠΠ°ΡΠ΅ΡΠΈΠ°Π» ΠΈ ΠΌΠ΅ΡΠΎΠ΄Ρ. Π ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠ΅ Π²ΠΊΠ»ΡΡΠ΅Π½ΠΎ 90 Π±ΠΎΠ»ΡΠ½ΡΡ
Π‘Π‘Π, ΠΊΠΎΡΠΎΡΡΡ
ΠΎΠ±ΡΠ»Π΅Π΄ΠΎΠ²Π°Π»ΠΈ ΠΊΠ°ΠΊ ΠΌΠΈΠ½ΠΈΠΌΡΠΌ Π΄Π²Π°ΠΆΠ΄Ρ β Π΄ΠΎ ΠΈ ΡΠ΅ΡΠ΅Π· 1β3,5 Π³ΠΎΠ΄Π° ΠΏΠΎΡΠ»Π΅ Π½Π°ΡΠ°Π»Π° Π»Π΅ΡΠ΅Π½ΠΈΡ Π Π’Π. ΠΠΎΡΠ΅ΡΠ½ΡΡ ΡΡΠ½ΠΊΡΠΈΡ ΠΎΡΠ΅Π½ΠΈΠ²Π°Π»ΠΈ ΠΏΠΎ ΡΠΊΠΎΡΠΎΡΡΠΈ ΠΊΠ»ΡΠ±ΠΎΡΠΊΠΎΠ²ΠΎΠΉ ΡΠΈΠ»ΡΡΡΠ°ΡΠΈΠΈ (Π‘ΠΠ€), ΡΠ°ΡΡΡΠΈΡΠ°Π½Π½ΠΎΠΉ ΠΏΠΎ ΡΠΎΡΠΌΡΠ»Π΅ CKD-EPI. ΠΠΏΡΠ΅Π΄Π΅Π»ΡΠ»ΠΈ ΡΠ°ΠΊΠΆΠ΅ ΡΡΠ°Π΄ΠΈΠΈ Ρ
ΡΠΎΠ½ΠΈΡΠ΅ΡΠΊΠΎΠΉ Π±ΠΎΠ»Π΅Π·Π½ΠΈ ΠΏΠΎΡΠ΅ΠΊ (Π₯ΠΠ), ΡΡΠΎΠ²Π΅Π½Ρ Π°ΡΡΠ΅ΡΠΈΠ°Π»ΡΠ½ΠΎΠ³ΠΎ Π΄Π°Π²Π»Π΅Π½ΠΈΡ, ΡΡΡΠΎΡΠ½ΡΡ ΠΏΡΠΎΡΠ΅ΠΈΠ½ΡΡΠΈΡ, ΠΊΠΎΠΆΠ½ΡΠΉ ΡΡΠ΅Ρ, Π°ΠΊΡΠΈΠ²Π½ΠΎΡΡΡ ΠΈ ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»ΠΈ Π»Π΅Π³ΠΎΡΠ½ΠΎΠΉ ΡΡΠ½ΠΊΡΠΈΠΈ β ΡΠΎΡΡΠΈΡΠΎΠ²Π°Π½Π½ΡΡ ΠΆΠΈΠ·Π½Π΅Π½Π½ΡΡ Π΅ΠΌΠΊΠΎΡΡΡ Π»Π΅Π³ΠΊΠΈΡ
ΠΈ Π΄ΠΈΡΡΡΠ·ΠΈΠΎΠ½Π½ΡΡ ΡΠΏΠΎΡΠΎΠ±Π½ΠΎΡΡΡ Π»Π΅Π³ΠΊΠΈΡ
.Β Β Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ ΠΈ ΠΎΠ±ΡΡΠΆΠ΄Π΅Π½ΠΈΠ΅. ΠΠ° ΡΠΎΠ½Π΅ ΠΊΠΎΠΌΠΏΠ»Π΅ΠΊΡΠ½ΠΎΠΉ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ Π Π’Π Π² ΠΊΠΎΠ½ΡΠ΅ Π½Π°Π±Π»ΡΠ΄Π΅Π½ΠΈΡ ΠΎΡΠΌΠ΅ΡΠ°Π»ΠΎΡΡ ΡΡΠ°ΡΠΈΡΡΠΈΡΠ΅ΡΠΊΠΈ Π·Π½Π°ΡΠΈΠΌΠΎΠ΅ ΡΠ½ΠΈΠΆΠ΅Π½ΠΈΠ΅ Π‘ΠΠ€ Π² Π³ΡΡΠΏΠΏΠ΅ Π±ΠΎΠ»ΡΠ½ΡΡ
Π² ΡΠ΅Π»ΠΎΠΌ. Π ΡΠΎ ΠΆΠ΅ Π²ΡΠ΅ΠΌΡ Ρ Π±ΠΎΠ»ΡΡΠΈΠ½ΡΡΠ²Π° ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ ΠΈΡΡ
ΠΎΠ΄Π½ΠΎ ΡΠΎΡ
ΡΠ°Π½Π½ΠΎΠΉ Π‘ΠΠ€ ΡΡΠ½ΠΊΡΠΈΡ ΠΏΠΎΡΠ΅ΠΊ ΠΎΡΡΠ°Π²Π°Π»Π°ΡΡ ΡΡΠ°Π±ΠΈΠ»ΡΠ½ΠΎΠΉ, Π° ΡΠΈΡΠ»ΠΎ Π±ΠΎΠ»ΡΠ½ΡΡ
Ρ Π₯ΠΠ ΡΠΌΠ΅Π½ΡΡΠΈΠ»ΠΎΡΡ Π½Π° 25 % β Ρ 20 Π΄ΠΎ 15. ΠΠΎΠ»Π΅Π΅ ΡΠ΅ΠΌ Ρ ΠΏΠΎΠ»ΠΎΠ²ΠΈΠ½Ρ Π±ΠΎΠ»ΡΠ½ΡΡ
, ΠΈΡΡ
ΠΎΠ΄Π½ΠΎ ΠΈΠΌΠ΅Π²ΡΠΈΡ
Π₯ΠΠ, ΠΏΠΎΡΠ»Π΅ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ Π‘ΠΠ€ ΡΠ²Π΅Π»ΠΈΡΠΈΠ»Π°ΡΡ (n = 11) ΠΈΠ»ΠΈ ΡΡΠ°Π±ΠΈΠ»ΠΈΠ·ΠΈΡΠΎΠ²Π°Π»Π°ΡΡ (n = 2), ΠΈ Π»ΠΈΡΡ Ρ 7 ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² ΠΎΠ½Π° ΡΡΠ°ΡΠΈΡΡΠΈΡΠ΅ΡΠΊΠΈ Π½Π΅Π·Π½Π°ΡΠΈΠΌΠΎ ΡΠ½ΠΈΠ·ΠΈΠ»Π°ΡΡ, ΠΏΡΠΈ ΡΡΠΎΠΌ ΡΠΎΠ»ΡΠΊΠΎ Π² 2 ΡΠ»ΡΡΠ°ΡΡ
Π½Π°Π±Π»ΡΠ΄Π°Π»ΠΎΡΡ ΡΠ°Π·Π²ΠΈΡΠΈΠ΅ Π±ΠΎΠ»Π΅Π΅ ΠΏΡΠΎΠ΄Π²ΠΈΠ½ΡΡΠΎΠΉ ΡΡΠ°Π΄ΠΈΠΈ Π₯ΠΠ. ΠΠ΅ΡΠ°Π»ΡΠ½ΠΎ ΡΠ°ΡΡΠΌΠΎΡΡΠ΅Π½Ρ ΡΠ΅Π·ΡΠ»ΡΡΠ°ΡΡ Π»Π΅ΡΠ΅Π½ΠΈΡ 2 Π±ΠΎΠ»ΡΠ½ΡΡ
, ΠΊΠΎΡΠΎΡΡΠ΅ ΡΠ°Π½Π΅Π΅ ΠΏΠ΅ΡΠ΅Π½Π΅ΡΠ»ΠΈ ΡΠΊΠ»Π΅ΡΠΎΠ΄Π΅ΡΠΌΠΈΡΠ΅ΡΠΊΠΈΠΉ ΠΏΠΎΡΠ΅ΡΠ½ΡΠΉ ΠΊΡΠΈΠ· (Π‘ΠΠ).Β Β ΠΠ°ΠΊΠ»ΡΡΠ΅Π½ΠΈΠ΅. Π Π΄Π°Π½Π½ΠΎΠΉ ΡΠ°Π±ΠΎΡΠ΅ Π½Π΅ ΠΎΡΠΌΠ΅ΡΠ΅Π½ΠΎ ΡΡΡΠ΅ΡΡΠ²Π΅Π½Π½ΠΎΠ³ΠΎ Π²Π»ΠΈΡΠ½ΠΈΡ Π»Π΅ΡΠ΅Π½ΠΈΡ Π Π’Π Π½Π° Π‘ΠΠ€ ΠΈ ΡΡΠ΅ΠΏΠ΅Π½Ρ Π₯ΠΠ. ΠΠΎΠ»ΡΡΠΈΠ½ΡΡΠ²ΠΎ Π±ΠΎΠ»ΡΠ½ΡΡ
ΠΈΠΌΠ΅Π»ΠΈ ΡΡΠ°Π±ΠΈΠ»ΡΠ½ΡΡ ΡΡΠ½ΠΊΡΠΈΡ ΠΏΠΎΡΠ΅ΠΊ, Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ ΠΈΡΡ
ΠΎΠ΄Π½ΠΎ Π½Π΅Π·Π½Π°ΡΠΈΡΠ΅Π»ΡΠ½ΠΎΠΉ ΡΡΠ΅ΠΏΠ΅Π½ΡΡ Π₯ΠΠ Π±ΡΠ»Π° Π²ΡΡΠ²Π»Π΅Π½Π° ΡΠ΅Π½Π΄Π΅Π½ΡΠΈΡ ΠΊ ΡΡΠ°Π±ΠΈΠ»ΠΈΠ·Π°ΡΠΈΠΈ ΠΏΠΎΡΠ΅ΡΠ½ΠΎΠΉ ΡΡΠ½ΠΊΡΠΈΠΈ. ΠΠ½Π°ΡΠΈΠΌΠΎΠ΅ ΡΠ½ΠΈΠΆΠ΅Π½ΠΈΠ΅ Π‘ΠΠ€ Π½Π° ΡΠΎΠ½Π΅ Π΄Π»ΠΈΡΠ΅Π»ΡΠ½ΠΎΠΉ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ, ΠΎΡΠΌΠ΅ΡΠ΅Π½Π½ΠΎΠ΅ Π² Π³ΡΡΠΏΠΏΠ΅ Π±ΠΎΠ»ΡΠ½ΡΡ
Π² ΡΠ΅Π»ΠΎΠΌ, ΠΏΠΎ-Π²ΠΈΠ΄ΠΈΠΌΠΎΠΌΡ, ΠΎΠ±ΡΡΡΠ½ΡΠ΅ΡΡΡ Π½Π°ΡΠ°ΡΡΠ°Π½ΠΈΠ΅ΠΌ ΠΏΠΎΡΠ΅ΡΠ½ΠΎΠΉ Π½Π΅Π΄ΠΎΡΡΠ°ΡΠΎΡΠ½ΠΎΡΡΠΈ Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ², ΠΈΡΡ
ΠΎΠ΄Π½ΠΎ ΠΈΠΌΠ΅Π²ΡΠΈΡ
Π²ΡΡΠ°ΠΆΠ΅Π½Π½ΠΎΠ΅ ΡΠΊΠ»Π΅ΡΠΎΠ΄Π΅ΡΠΌΠΈΡΠ΅ΡΠΊΠΎΠ΅ ΠΏΠΎΡΠ°ΠΆΠ΅Π½ΠΈΠ΅ ΠΏΠΎΡΠ΅ΠΊ, Π² ΡΠ°ΡΡΠ½ΠΎΡΡΠΈ, Π²ΡΠ»Π΅Π΄ΡΡΠ²ΠΈΠ΅ Π‘ΠΠ. Π’ΡΠ΅Π±ΡΠ΅ΡΡΡ Π΄Π°Π»ΡΠ½Π΅ΠΉΡΠ΅Π΅ ΠΈΠ·ΡΡΠ΅Π½ΠΈΠ΅ Π²Π»ΠΈΡΠ½ΠΈΡ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ Π Π’Π Π½Π° ΡΡΠ½ΠΊΡΠΈΡ ΠΏΠΎΡΠ΅ΠΊ Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ Π‘Π‘Π